- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Iovance Biotherapeutics Inc (IOVA)
Iovance Biotherapeutics Inc stock price live, this page displays NASDAQ IOVA stock exchange data. View the IOVA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Iovance Biotherapeutics Inc real time stock price chart below.
What Is the Iovance Biotherapeutics Inc Stock Price Today?
The Iovance Biotherapeutics Inc stock price today is 2.08.
What Is the Stock Symbol for Iovance Biotherapeutics Inc?
The stock symbol for Iovance Biotherapeutics Inc is "IOVA."
What Stock Exchange Does Iovance Biotherapeutics Inc Trade On?
Iovance Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Iovance Biotherapeutics Inc a Good Stock to Buy?
Determining whether Iovance Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IOVA quote. (ISIN: US4622601007)
What Is the Iovance Biotherapeutics Inc Stock Price Today?
The Iovance Biotherapeutics Inc stock price today is 2.08.
What Is the Stock Symbol for Iovance Biotherapeutics Inc?
The stock symbol for Iovance Biotherapeutics Inc is "IOVA."
What Stock Exchange Does Iovance Biotherapeutics Inc Trade On?
Iovance Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Iovance Biotherapeutics Inc a Good Stock to Buy?
Determining whether Iovance Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IOVA quote. (ISIN: US4622601007)
2.08
-0.17(-7.37%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.01
2.22
52 wk Range
1.64
12.51
IOVA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IOVA is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.012.22
52 wk Range
1.6412.51
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IOVA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
10.70
Upside
+414.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- iovance cfo resigns to pursue new opportunities
- Investing.com
- iovance cfo resigns to pursue new opportunities
- Investing.com
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics Inc SWOT Analysis
Immunotherapy Pionee | Iovance Biotherapeutics leads in tumor-infiltrating lymphocyte therapy, with promising results in melanoma and non-small cell lung cancer treatments |
Financial Health | Strong Q3 2024 performance with $58.6M revenue, $403.8M cash position. Analyst targets range from $5 to $32, suggesting potential undervaluation |
Market Opportunities | Explore Iovance's potential in the melanoma market, with Amtagvi projected to achieve peak sales exceeding $1.5 billion in second-line plus setting |
Challenges Ahead | Learn about Iovance's strategies to navigate a competitive landscape, regulatory hurdles, and the need for continued clinical success in a rapidly evolving secto |
Iovance Biotherapeutics Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS of -$0.36 missed forecast by $0.12; revenue of $49.3M fell short of $83.27M expectation
- Stock plunged 43.86% in after-hours trading to $1.78, reflecting investor disappointment
- Full-year revenue guidance revised to $250-$300M; company anticipates growth in patient infusions and international expansion
- Management remains confident in peak U.S. sales opportunity of over $1B despite operational challenges
- Analysts expect 176% revenue growth this year; company maintains strong liquidity with current ratio of 3.74
Last Updated: 09-05-2025, 03:16 am
Read Full TranscriptCompare IOVA to Peers and Sector
Metrics to compare | IOVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIOVAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −2.3x | −0.5x | |
PEG Ratio | −0.06 | 0.02 | 0.00 | |
Price/Book | 0.9x | 0.4x | 2.6x | |
Price / LTM Sales | 3.3x | 5.2x | 3.1x | |
Upside (Analyst Target) | 301.8% | 373.1% | 51.1% | |
Fair Value Upside | Unlock | 46.4% | 8.9% | Unlock |
Analyst Ratings
8 Buy
4 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 10.70
(+414.42% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.36 / -0.24
Revenue / Forecast
49.30M / 83.27M
FAQ
What Is the Iovance Biotherapeutics (IOVA) Stock Price Today?
The Iovance Biotherapeutics stock price today is 2.08.
What Stock Exchange Does Iovance Biotherapeutics Trade On?
Iovance Biotherapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Iovance Biotherapeutics?
The stock symbol for Iovance Biotherapeutics is "IOVA."
What Is the Iovance Biotherapeutics Market Cap?
As of today, Iovance Biotherapeutics market cap is 694.58M.
What Is Iovance Biotherapeutics's Earnings Per Share (TTM)?
The Iovance Biotherapeutics EPS (TTM) is -1.23.
When Is the Next Iovance Biotherapeutics Earnings Date?
Iovance Biotherapeutics will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is IOVA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Iovance Biotherapeutics Stock Split?
Iovance Biotherapeutics has split 2 times.
How Many Employees Does Iovance Biotherapeutics Have?
Iovance Biotherapeutics has 838 employees.
What is the current trading status of Iovance Biotherapeutics (IOVA)?
As of 16 Jun 2025, Iovance Biotherapeutics (IOVA) is trading at a price of 2.08, with a previous close of 2.24. The stock has fluctuated within a day range of 2.01 to 2.22, while its 52-week range spans from 1.64 to 12.51.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.